A current update on the use of clinical neuropsychology in epilepsy and its future outlook Clinical neurology has still not managed to clear a way in the daily practice with patients with all types of epilepsy despite significant advances in cognitive neuroscience and a large number of clinical studies on epilepsy and cognition.

	How is it that there are only rarely major advances in the field of clinical neuropsychology? It has long been time for this question to be asked, and for an attempt to be made to bring about changes. This was the aim of the Progress in Epileptic Disorders workshop held in Toronto and the result of this book.

Progress in epileptic disorders ; neuropsychology in the care of people with epilepsy

More than 12 million people with epilepsy have seizures that cannot be controlled by antiepileptic drugs. The term "drug-resistance" is abundantly used in the epilepsy literature but the definitions proposed differ considerably. It is used indifferently in a number of different settings: as a criterion for selection of patients eligible for new antiepileptic drug trials, for the selection of surgical candidates, for the design of epidemiological studies, for the design of studies on quality of life, for the definition of the epileptic encephalopathies (in comparison to more benign epilepsy syndromes), to mention but a few. As a result, available studies are usually not comparable and referral to epilepsy specialists is unacceptably delayed.

The present volume of Progress in Epileptic Disorders includes several focused chapters on all issues relating to drug-resistance and offers the basis for a consensus on a clinically meaningful core definition.

Drug-Resistant Epilepsies

Epilepsies partielles graves pharmaco-résistantes de l'enfant : stratégies diagnostiques et traitements chirurgicaux.

Ses oeuvres

Ses derniers livres